WGC
EW icon

Watts Gwilliam & Co’s Edwards Lifesciences EW Stock Holding History

Watts Gwilliam & Co’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$223K Hold
2,864
– – 0.04% 203
2025
Q2 		$214K Sell
2,864
-36
-1% -$2.69K 0.04% 206
2025
Q1 		$210K Buy
+2,900
New +$208K 0.05% 196

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return

Watts Gwilliam & Co's EW Position: Q3 2025 in Review

Watts Gwilliam & Co held its Edwards Lifesciences (EW) position steady in Q3 2025 at 2,864 shares worth $223K. The position accounts for 0.04% of the portfolio, ranked #203.

Watts Gwilliam & Co first reported a position in EW in Q1 2025 and has held it in 3 quarters since. 1,253 funds tracked by Wall St. Rank hold EW as of Q3 2025.

  • Watts Gwilliam & Co held 2,864 shares of Edwards Lifesciences worth $223K as of Q3 2025.
  • Watts Gwilliam & Co left its Edwards Lifesciences share count unchanged in Q3 2025.
  • Edwards Lifesciences made up 0.04% of Watts Gwilliam & Co's portfolio in Q3 2025, its #203 holding.
  • Watts Gwilliam & Co first reported a position in Edwards Lifesciences in Q1 2025 and has held it in 3 quarters since.
  • 1,253 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2025.

Based on Watts Gwilliam & Co's 13F filing for Q3 2025, filed 21 Nov 2025.